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Introduction
Inflammation followed by bacterial and viral infections triggers high risk of cancer and promote tumor development and progression (1, 2) . Long-term use of anti-inflammatory drugs has been shown to reduce the risk of cancer, if not all, as demonstrated by a clinical study of aspirin and colorectal cancer occurrence (3) .
Inflammatory cytokines facilitate tumor progression and metastasis in most cases.
Innate immune response and following cellular events are closely concerned with the formation of tumor microenvironment (4, 5) .
By contrast, inflammation induced by microbial preparations was applied to patients with cancer for therapeutic potential as Coley vaccine with some success. A viral replication product, double-stranded (ds)RNA and its analog polyI:C (6,7), induced acute inflammation, and has been expected to be a promising therapeutic agent against cancer. Although polyI:C exerts life-threatening cytokinemia (8) , trials for its clinical use as an adjuvant still remain continued because of its high therapeutic potential (9, 10) .
Pathogen-associated molecular patterns (PAMPs) and host cell factors induced secondary to PAMP-host cell interaction act as a double-edged sword in cancer prognosis and require the understanding their multifarious functional properties in tumor environment.
Recent advance on the study of innate immunity demonstrates how polyI:C suppress tumor progression (11) . PolyI:C is a synthetic compound, that serves as an agonist for pattern-recognition receptors (PRRs), Toll-like receptor (TLR)3 and melanoma differentiation-associated protein (MDA)5 (12) (13) (14) . Although TLR3 and MDA5 signals are characterized as MyD88-independent (16, 17) , they have immune-effector-inducing properties (12) (13) (14) (15) . TLR3 couples with the Toll-interleukin 1 receptor domain (TIR)-containing adaptor molecule (TICAM)-1 (also known as TRIF), and MDA5 couples with the interferon (IFN) β promoter stimulator (IPS)-1 (also known as Cardif, MAVS, or VISA) (11, 15) . Possible functions for the TICAM-1 and IPS-1 signaling pathways have been investigated by using gene-disrupted mice (15) . Although they activate the same downstream transcription factors nuclear factor (NF)-κB and interferon regulatory factor (IRF)-3 (15, 18) , they appear to distinctly modulate myeloid dendritic cells (mDC) and macrophages (Mf) to drive effector lymphocytes (19, 20) .
Tumor microenvironment frequently involves myeloid-derived suppressor cells (MDSC), tumor-associated macrophages (TAM), and immature myeloid dendritic cells (mDCs) (1, 21) . They express PRR through which they are functionally activated. Once the inflammation process is triggered, immature mDCs turn mature so that they are capable of antigen cross-presentation and able to activate immune effector cells, which would act to protect the host system and damage the undesirable tumor cells (22) . On the other hand, TAM and MDSC play a major role in establishing a favorable environment for tumor cell development by suppressing antitumor immunity and recruiting host immune cells to support tumor cell survival, motility and invasion (23) (24) (25) . Although these myeloid cell scenarios have been studied with interest, how the PRR signal in these myeloid cells links regulation of tumor progression has yet to be elucidated.
Here we show that TICAM-1 but not IPS-1 signal in tumor-infiltrating Mf is engaged in conversion of the TAM-like Mf to tumoricidal effectors. We investigated the molecular mechanisms in Mf underlying the phenotype switch from tumor-supporting to tumor-suppressing by treating cells with polyI:C and found that the TICAM-1-inducing tumor necrosis factor (TNF)-α and M1 polarization are crucial for eliciting tumoricidal activity in TAM.
Results
In vivo effect of polyI:C on implant 3LL tumor
Intraperitoneal (i.p.) injection of polyI:C rapidly induced hemorrhagic necrosis in 3LL tumors implanted in WT mice, which was established >12 h after polyI:C treatment ( Figure 1A ). The polyI:C-dependent hemorrhagic necrosis did not occur in TNF-α-/-mice ( Figure 1A ). Histological and immunohistochemical analysis revealed vascular damage in the necrotic lesion, where disruption of vascular endothelial cells was indicated by fragmented CD31 + marker ( Figure S1 ). Although the polyI:C signal is delivered by TICAM-1 and IPS-1 adaptors (11, 13) , the hemorrhagic necrosis was largely alleviated in TICAM-1-/-mice but not in IPS-1-/-mice ( Figure 1A ). The results suggest that polyI:C is a reagent that induces 3LL hemorrhagic necrosis, and the TICAM-1 pathway and its products, including TNF-α, are preferentially involved in this response.
3LL implant tumors grew well in wild-type (WT) C57BL6 mice. polyI:C, when i.p. injected, resulted in tumor growth retardation ( Figure 1B ). The retardation of tumor growth by polyI:C was also impaired in TNF-α-/-mice ( Figure 1B ), suggesting that TNF-α is a critical effector for not only induction of hemorrhagic necrosis but also further 3LL tumor regression. To investigate the signaling pathway involved in the tumor growth retardation by polyI:C, we challenged WT, MyD88-/-, TICAM-1-/-and IPS-1-/-mice with 3LL implantation and then treated the mice with i.p. injection of polyI:C. 3LL growth retardation was observed in both IPS-1-/-( Figure 1C ) and MyD88-/-mice, to a similar extent to WT mice. In contrast, polyI:C-dependent tumor growth retardation was abrogated in TICAM-1-/-mice ( Figure 1D ). The size differences of the implanted tumors became significant within two days after polyI:C treatment, suggesting that the molecular effector for tumor regression is induced early and its up-stream is TICAM-1. Similar results were obtained with MC38 implant tumor ( Figure   S2A ), which is TNF-α-sensitive and MHC class I-positive (Table S1, 26) .
PolyI:C is a reagent that induces NK cell activation in MHC class I-negative tumors (12) and 3LL cells are actually class I-negative and NK cell-sensitive (Table S1 ) (27, 28) . 
PolyI:C induces TNF-α through the TICAM-1 pathway in mice
To test whether polyI:C treatment had elicited TNF-α production in vivo, we investigated the cytokine profiles of serum from polyI:C-stimulated WT and IPS-1-/-and TICAM-1-/-mice by enzyme-linked immunosorbent assay (ELISA). Prominent differences in TNF-α levels were observed in serum collected from polyI:C-injected WT and TICAM-1-/-mice. Serum TNF-α levels in WT and IPS-1-/-mice were significantly higher than that in TICAM-1-/-mice within 1 h after polyI:C injection ( Figure S4A -B). Interferon (IFN)-β is a main output for polyI:C stimulation (11), and its production was decreased in TICAM-1-/-mice and totally abrogated in IPS-1-/-mice ( Figure S4C ). Taken together, the data indicate that the TICAM-1 pathway was able to sustain a high TNF-α level in the early phase of polyI:C treatment, which is independent of IPS-1 and subsequent production of IFN-β.
TICAM-1+ cells in tumor produces TNF-α in response to polyI:C stimulation
Using the 3LL-implant WT, IPS-1-/-and TICAM-1-/-mouse models, we tested whether polyI:C-induced early TNF-α was responsible for the lately observed tumor regression. Time-course analyses of the polyI:C-induced TNF-α protein levels were performed by ELISA using serum samples and tumors extracted from the experimental mice. The tumor TNF-α levels in WT and IPS-1-/-mice increased at 2 h post polyI:C i.p. injection ( Figure 2A ). The serum TNF-α levels in both were rapidly up-regulated within 1 h post polyI:C injection, although in WT the levels continued to increase but in IPS-1-/-mice gradually decreased ( Figure 2B ). In TICAM-1-/-mice, however, no appreciable up-regulation of TNF-α protein was detected in either tumor or serum samples, during the early time-course tested. To test whether the induced TNF-α protein was generated de novo in tumors, we examined the corresponding mRNA levels in excised tumors ( Figure 2C ). The TNF-α mRNA levels peaked between 1 and 2 h after polyI:C injection, while the TNF-α protein level was kept high at >2 h after polyI:C injection in tumor as well as serum. In the TICAM-1-/-mice, TNF-α production was largely abrogated in the tumor and serum samples, suggesting that TNF-α was mainly In line with our findings, virus infection has been observed to instigate tumor regression in patients with cancer (36, 54) . Gene therapy for cancer patients using virus-derived vectors has proved effective in reducing tumors in clinic (36, 37) .
Administration of dsRNA elicites IFN induction, NK cell activation and CTL proliferation for antitumor effectors in vivo (19, 55) . This is the first notion that tumor-infiltrating Mf is a target of dsRNA and converted from a tumor-supporter to a tumoricidal effector. Hence, the antitumor effect of dsRNA adjuvant is ultimately based on the liberation of type I IFN, functional maturation of mDC, and modulation of tumor-infiltrating Mf, where TICAM-1 is a crucial transducer in eliciting antitumor immunity.
Methods
Mice and tumor cells. Inbred C57BL/6 wild-type (WT) mice were purchased from Clea Japan. TICAM1 -/-and IPS-1 -/-mice were generated in our laboratory and were maintained as described previously. IRF-3/7 double KO mice were a gift from Dr. T.
Taniguchi (Univ. Tokyo, Japan). TNF-α-/-mice were kindly provided by Dr. A. Nakane 
